Silymarin Cream Versus Salicylic Acid in Treatment of Acne Vulgaris
NCT ID: NCT04490967
Last Updated: 2021-03-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-04-30
Study Completion Date
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acne vulgaris is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. Acne vulgaris is an extremely common condition with a lifetime prevalence of approximately 85% and occurs mostly during adolescence.
Acne vulgaris leads to significant morbidity that is associated with residual scarring and psychological disturbances such as poor self-image, depression, and anxiety, which leads to a negative impact on quality of life.
The treatment of acne vulgaris is challenging and often chronic, with high rates of failure and numerous choices. Frequent evaluations (i.e., every 8-12 weeks) are important to enable appropriate monitoring, manage adverse effects, and evaluate for medication compliance.
Topical therapies are considered one of the mainstay treatments for patients with mild-to-moderate acne.
Acne vulgaris leads to significant morbidity that is associated with residual scarring and psychological disturbances such as poor self-image, depression, and anxiety, which leads to a negative impact on quality of life.
The treatment of acne vulgaris is challenging and often chronic, with high rates of failure and numerous choices. Frequent evaluations (i.e., every 8-12 weeks) are important to enable appropriate monitoring, manage adverse effects, and evaluate for medication compliance.
Topical therapies are considered one of the mainstay treatments for patients with mild-to-moderate acne.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma
NCT05099601
Melasma
UNKNOWN
PHASE4
Comparison of Two Salicylic Acid Formulations
NCT00848744
Acne Vulgaris
COMPLETED
NA
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris
NCT05536193
Acne Vulgaris
UNKNOWN
PHASE4
Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris
NCT05666765
Acne Vulgaris
UNKNOWN
PHASE4
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
NCT05497323
Acne Vulgaris
UNKNOWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chemical peeling is one of the most common cosmetic procedures in medical practice and has been used for decades. It is defined as the application of chemical agents, of variable strength, on the skin that results in controlled destruction of the epidermis and dermis. The induced exfoliation is followed by dermal and epidermal regeneration from adjacent epithelium and skin adnexa, which results in improved surface texture and appearance of the skin. This is a simple and cost-effective procedure with several dermatological applications.
Salicylic acid is a 2-hydroxybenzoic acid used for superficial peeling due to its strong keratolytic and comedolytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum. These chemical properties explain its popularity and success in acne patients. Also, it has well-documented anti-inflammatory properties.
Silymarin is a standardized extract from S. marianum seeds, is traditionally used as a hepatoprotective agent for its potent regenerative properties. Lately, Silymarin is utilized in dermatological and cosmetic preparations for its antioxidant effect anti-inflammatory and immunomodulatory properties.
Various studies have been created to evaluate the efficacy of Silymarin in UV protection, prevention against skin cancer and against actinic keratosis.
Silymarin showed efficacy the treatment of Rosacea, Melasma, Vitiligo, Psoriasis, atopic dermatitis and contact dermatitis . Other studies showed that Silymarin has anti aging properties and potential action for wound healing .
Salicylic acid is a 2-hydroxybenzoic acid used for superficial peeling due to its strong keratolytic and comedolytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum. These chemical properties explain its popularity and success in acne patients. Also, it has well-documented anti-inflammatory properties.
Silymarin is a standardized extract from S. marianum seeds, is traditionally used as a hepatoprotective agent for its potent regenerative properties. Lately, Silymarin is utilized in dermatological and cosmetic preparations for its antioxidant effect anti-inflammatory and immunomodulatory properties.
Various studies have been created to evaluate the efficacy of Silymarin in UV protection, prevention against skin cancer and against actinic keratosis.
Silymarin showed efficacy the treatment of Rosacea, Melasma, Vitiligo, Psoriasis, atopic dermatitis and contact dermatitis . Other studies showed that Silymarin has anti aging properties and potential action for wound healing .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Acne Vulgaris
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Patients will use salicylic acid 30% peeling on the right side of the face and topical Silymarin 1.4% cream on the left side.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Silymarin and salicylic acid
There will be one group of patients, that will use salicylic acid peeling on the right side of the face and topical Silymarin cream on the left side
Group Type
EXPERIMENTAL
Silymarin
Intervention Type
COMBINATION_PRODUCT
Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
Salicylic acid
Intervention Type
PROCEDURE
Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Silymarin
Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
Intervention Type
COMBINATION_PRODUCT
Salicylic acid
Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Silybin, Silybum, Marian thistle.
2-hydroxybenzoic acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients older than 18 years of age.
* Patients with mild and moderate acne vulgaris.
* Patients with Fitzpatrick skin type III, IV and V.
* Patients with mild and moderate acne vulgaris.
* Patients with Fitzpatrick skin type III, IV and V.
Exclusion Criteria
* Severe acne.
* Patients under treatment with contraceptive pills or any kind of systemic or topic acne medication (isotretinoin, antibiotics, topical products).
* History of hypertrophic/keloid scar formation.
* Pregnancy.
* Recurrent herpes infection.
* Patients under treatment with contraceptive pills or any kind of systemic or topic acne medication (isotretinoin, antibiotics, topical products).
* History of hypertrophic/keloid scar formation.
* Pregnancy.
* Recurrent herpes infection.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alaa Gamal Ahmed Makhlouf
Principal investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013 Mar;168(3):474-85. doi: 10.1111/bjd.12149.
Reference Type
BACKGROUND
Ramos-e-Silva M, Ramos-e-Silva S, Carneiro S. Acne in women. Br J Dermatol. 2015 Jul;172 Suppl 1:20-6. doi: 10.1111/bjd.13638.
Reference Type
BACKGROUND
Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol. 2012 Oct;51(10):1162-74. doi: 10.1111/j.1365-4632.2012.05519.x.
Reference Type
BACKGROUND
Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, Ganceviciene R, Haedersdal M, Layton A, Lopez-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Rzany B, Sammain A, Simonart T, Veien NK, Zivkovic MV, Zouboulis CC, Gollnick H; European Dermatology Forum. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012 Feb;26 Suppl 1:1-29. doi: 10.1111/j.1468-3083.2011.04374.x. No abstract available.
Reference Type
BACKGROUND
Al-Talib H, Al-Khateeb A, Hameed A, Murugaiah C. Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris. An Bras Dermatol. 2017 Mar-Apr;92(2):212-216. doi: 10.1590/abd1806-4841.20175273.
Reference Type
BACKGROUND
Rendon MI, Berson DS, Cohen JL, Roberts WE, Starker I, Wang B. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol. 2010 Jul;3(7):32-43.
Reference Type
BACKGROUND
Clark E, Scerri L. Superficial and medium-depth chemical peels. Clin Dermatol. 2008 Mar-Apr;26(2):209-18. doi: 10.1016/j.clindermatol.2007.09.015.
Reference Type
BACKGROUND
Arif T. Salicylic acid as a peeling agent: a comprehensive review. Clin Cosmet Investig Dermatol. 2015 Aug 26;8:455-61. doi: 10.2147/CCID.S84765. eCollection 2015.
Reference Type
BACKGROUND
Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg. 2003 Dec;29(12):1196-9; discussion 1199. doi: 10.1111/j.1524-4725.2003.29384.x.
Reference Type
BACKGROUND
Handog EB, Datuin MS, Singzon IA. Chemical peels for acne and acne scars in asians: evidence based review. J Cutan Aesthet Surg. 2012 Oct;5(4):239-46. doi: 10.4103/0974-2077.104911.
Reference Type
BACKGROUND
Vaid M, Katiyar SK. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol. 2010 May;36(5):1053-60. doi: 10.3892/ijo_00000586.
Reference Type
BACKGROUND
Surai PF. Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives. Antioxidants (Basel). 2015 Mar 20;4(1):204-47. doi: 10.3390/antiox4010204.
Reference Type
BACKGROUND
Katiyar SK, Mantena SK, Meeran SM. Silymarin protects epidermal keratinocytes from ultraviolet radiation-induced apoptosis and DNA damage by nucleotide excision repair mechanism. PLoS One. 2011;6(6):e21410. doi: 10.1371/journal.pone.0021410. Epub 2011 Jun 22.
Reference Type
BACKGROUND
Meeran SM, Katiyar S, Elmets CA, Katiyar SK. Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice. Mol Cancer Ther. 2006 Jul;5(7):1660-8. doi: 10.1158/1535-7163.MCT-06-0095.
Reference Type
BACKGROUND
Katiyar SK, Meleth S, Sharma SD. Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV-induced oxidative stress through targeting infiltrating CD11b+ cells in mouse skin. Photochem Photobiol. 2008 Mar-Apr;84(2):266-71. doi: 10.1111/j.1751-1097.2007.00241.x. Epub 2007 Nov 28.
Reference Type
BACKGROUND
Katiyar SK. Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol. 2002 Dec;21(6):1213-22.
Reference Type
BACKGROUND
Vaid M, Prasad R, Singh T, Elmets CA, Xu H, Katiyar SK. Silymarin inhibits ultraviolet radiation-induced immune suppression through DNA repair-dependent activation of dendritic cells and stimulation of effector T cells. Biochem Pharmacol. 2013 Apr 15;85(8):1066-76. doi: 10.1016/j.bcp.2013.01.026. Epub 2013 Feb 5.
Reference Type
BACKGROUND
Vaid M, Prasad R, Sun Q, Katiyar SK. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One. 2011;6(7):e23000. doi: 10.1371/journal.pone.0023000. Epub 2011 Jul 28.
Reference Type
BACKGROUND
Chatterjee ML, Agarwal R, Mukhtar H. Ultraviolet B radiation-induced DNA lesions in mouse epidermis: an assessment using a novel 32P-postlabelling technique. Biochem Biophys Res Commun. 1996 Dec 13;229(2):590-5. doi: 10.1006/bbrc.1996.1848.
Reference Type
BACKGROUND
Berman B, Amini S. Pharmacotherapy of actinic keratosis: an update. Expert Opin Pharmacother. 2012 Sep;13(13):1847-71. doi: 10.1517/14656566.2012.716039.
Reference Type
BACKGROUND
Berardesca E, Cameli N, Cavallotti C, Levy JL, Pierard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol. 2008 Mar;7(1):8-14. doi: 10.1111/j.1473-2165.2008.00355.x.
Reference Type
BACKGROUND
Svobodova A, Zdarilova A, Walterova D, Vostalova J. Flavonolignans from Silybum marianum moderate UVA-induced oxidative damage to HaCaT keratinocytes. J Dermatol Sci. 2007 Dec;48(3):213-24. doi: 10.1016/j.jdermsci.2007.06.008. Epub 2007 Aug 3.
Reference Type
BACKGROUND
Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012 Oct 2;12:18. doi: 10.1186/1471-5945-12-18.
Reference Type
BACKGROUND
Sehgal VN. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo. J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1218-9. doi: 10.1111/j.1468-3083.2009.03128.x. Epub 2009 Mar 3. No abstract available.
Reference Type
BACKGROUND
Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experientia. 1979 Dec 15;35(12):1548-60. doi: 10.1007/BF01953184.
Reference Type
BACKGROUND
Koch HP, Bachner J, Loffler E. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13.
Reference Type
BACKGROUND
Kang JS, Yoon WK, Han MH, Lee H, Lee CW, Lee KH, Han SB, Lee K, Yang KH, Park SK, Kim HM. Inhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. Int Immunopharmacol. 2008 Oct;8(10):1475-80. doi: 10.1016/j.intimp.2008.06.004. Epub 2008 Jun 30.
Reference Type
BACKGROUND
Mady FM, Essa H, El-Ammawi T, Abdelkader H, Hussein AK. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Des Devel Ther. 2016 Mar 10;10:1101-10. doi: 10.2147/DDDT.S103423. eCollection 2016.
Reference Type
BACKGROUND
Han MH, Yoon WK, Lee H, Han SB, Lee K, Park SK, Yang KH, Kim HM, Kang JS. Topical application of silymarin reduces chemical-induced irritant contact dermatitis in BALB/c mice. Int Immunopharmacol. 2007 Dec 15;7(13):1651-8. doi: 10.1016/j.intimp.2007.08.019. Epub 2007 Sep 14.
Reference Type
BACKGROUND
Pientaweeratch S, Panapisal V, Tansirikongkol A. Antioxidant, anti-collagenase and anti-elastase activities of Phyllanthus emblica, Manilkara zapota and silymarin: an in vitro comparative study for anti-aging applications. Pharm Biol. 2016 Sep;54(9):1865-72. doi: 10.3109/13880209.2015.1133658. Epub 2016 Feb 24.
Reference Type
BACKGROUND
Sharifi R, Rastegar H, Kamalinejad M, Dehpour AR, Tavangar SM, Paknejad M, Mehrabani Natanzi M, Ghannadian N, Akbari M, Pasalar P. Effect of topical application of silymarin (Silybum marianum) on excision wound healing in albino rats. Acta Med Iran. 2012;50(9):583-8.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMVSA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris
NCT00361322
COMPLETED
PHASE1/PHASE2
Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris
NCT00624676
COMPLETED
NA
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
NCT05469880
COMPLETED
NA
Conventional Photodynamic Therapy Versus Daylight Photodynamic Therapy for The Treatment of Acne Vulgaris
NCT04631250
COMPLETED
NA
Use of Alternative Therapy in Acne Vulgaris Patients
NCT04538729
COMPLETED
Combined Salicylic and Azaleic Acid Verus Trichloroacetic Acid 25% Peel in Treatment of Acne
NCT03071549
COMPLETED
PHASE3
Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris
NCT01245946
COMPLETED
PHASE2
The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol
NCT06775314
NOT_YET_RECRUITING
PHASE3
Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study
NCT00206895
COMPLETED
NA
Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris
NCT05712837
COMPLETED
NA
Assessment of the Effects of Silk Pillowcases on Acne Prone Skin
NCT06142487
NOT_YET_RECRUITING
NA
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
NCT01446237
COMPLETED
NA
Efficacy of Different Types of Chemical Peels in the Treatment of Acne Vulgaris
NCT07240051
COMPLETED
NA
Cutaneous Acceptability, Comedogenic Potential and Efficacy of Two Cosmetic Products Used in Synergy
NCT05490537
COMPLETED
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris
NCT07250880
NOT_YET_RECRUITING
The Benefit of a Deep Cleansing Gel in the Management of Mild to Moderate Truncal Acne
NCT05584150
COMPLETED
A Study to Assess the Safety and Efficacy of a Sunscreen on Acne-Prone Skin With Inflammatory and Non-Inflammatory Acne Vulgaris
NCT06544889
COMPLETED
NA
Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vulgaris
NCT00767104
COMPLETED
NA
A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma
NCT01976286
ACTIVE_NOT_RECRUITING
NA
Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
NCT00787943
COMPLETED
NA
Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA
NCT03039634
COMPLETED
Clinico-demographic Features of Patients With Acne Vulgaris
NCT05061615
UNKNOWN
Efficacy of a Deep Cleansing Gel Containing 2% Salicylic Acid, 0.2% Zinc Gluconate and 0.05% Lipohydroxy Acid in the Management of Mild to Moderate Facial Acne
NCT05779085
COMPLETED
Social Media Use of Acne Vulgaris Patients: Multicenter, Survey Work
NCT04538703
UNKNOWN
Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne
NCT01629797
COMPLETED
NA